Feeling sick made some women give up
PT-141 side effects sometimes made women stop despite improved desire.
A sick stomach can make a small benefit feel hardly worth having. Some women stopped for that reason. Your heart health matters before treatment too. Accounts of self-testing with laboratory supplies don't give a dependable risk for you.
The main warning is common nausea and risk to the heart
Feeling sick was the most common PT-141 side effect, followed by redness and headaches [4]. During longer treatment, about 40% of women reported nausea [4]. More stopped because of sickness than because of other unwanted effects. I'd ask your doctor what your heart history adds to those concerns.
The medicine briefly raises blood pressure while slowing your pulse a little. Heart disease or high blood pressure that isn't controlled means the drug can't be used [11]. Frequent use may also leave lasting dark patches on gums or skin. You need those risks weighed against a small benefit in a specific group of women.
People testing laboratory supplies on themselves also describe feeling ill and unwanted skin changes. Their public accounts haven't been checked against placebo shots, which contain no active drug and help researchers see whether a change follows the medicine or happens even without the medicine. These accounts don't measure your risk of an unwanted effect.
During longer treatment, sickness made some women stop
A 52-week study enrolled 684 women for continued bremelanotide treatment [4]. Some left before the year ended. Women most often reported sickness, headaches, and hot, reddened skin during treatment. Each woman knew she was getting medicine, and nobody received placebo for comparison.
Study participants also reported stuffy noses and reactions around injection spots [3][4]. Women most often gave up because of nausea. The instructions warn that blood pressure rises briefly and the pulse slows [11]. Those effects help explain why your doctor needs to check heart health.
The instructions also describe the body removing the drug within hours [11]. Researchers traced a test amount as the body broke the medicine apart. Most left in urine, and some left in stool. A sexual effect can outlast the higher drug level in blood.
Frequent use can leave dark patches on the face or gums
Frequent use can deepen the color of the face, gums, or breasts [11]. The medicine stimulates cells that make melanin, the substance responsible for skin color. Darkening can happen separately from any improvement in sexual interest. Your doctor can explain why the same drug has both effects.
Skin that becomes briefly hot and red is a different reaction. The redness passes, while darkened areas can remain once treatment has ended. Frequent use is a known reason these patches can develop. Ask about lasting skin changes when you discuss the possible benefit.
PT-141 for men has early findings without an approved treatment
PT-141 for men remains outside approval; the approved treatment concerns women [6]. Early tests found erections soon after men received the drug [1]. Larger amounts produced greater responses, but the finding doesn't establish lasting relief. Nose-spray testing found responses above roughly 7 milligrams, as an experimental finding rather than instructions for you.
In June 2024, the developer announced Phase 2 testing in about 50 patients [13]. This is early testing of benefit before the larger studies needed for approval. These men hadn't improved with an erection pill alone, so researchers planned to add bremelanotide. They also investigated making a single product with the two medicines together [13].
The announcement didn't report whether the men improved with both medicines. An early erection response doesn't establish dependable help with your sexual difficulty. Ask your doctor whether a study tested men with symptoms like yours. The claims about male treatment still need firmer findings before you can judge the benefit.
Separate a prescription from proof of benefit in men: Promise Peptides includes PT-141 (bremelanotide) in the medications it now prescribes at mypromise.com, but its licensed U.S. clinician can refuse after assessing the person. Its clinical care reaches only patients in the United States, and both state rules and the treatment considered can limit that care. A compounded version has no FDA approval; the cited record still leaves PT-141 use in men off-label, investigational, and without established benefit.
A disputed paper and uncertain bottle contents weaken some claims
A journal raised doubts in 2023 about a bremelanotide study published in 2008. The paper concerned men with erection problems. The formal notice, Expression of Concern, means the paper's trustworthiness is in question. Your doctor can check whether a claim depends on that disputed study.
Laboratory PT-141 supplies don't undergo the checks required for approved prescription medicine [11]. You can't rely on their label to prove what the bottle holds or how strong the contents are. That uncertainty can add harm beyond the drug's known effects. A medicine name alone doesn't assure you of what a bottle holds.
The World Anti-Doping Agency sets rules about prohibited drug use in sport. Its rules cover unapproved drugs that act like PT-141 on proteins receiving hormone messages. Athletes need current guidance to check whether a particular product is prohibited. The rule doesn't settle the status of every product with that name.
Bremelanotide isn't a U.S. controlled substance, meaning a drug under special legal limits because of abuse risk. That legal status doesn't remove the need for a prescription for approved treatment. Nor does the status establish safety or approval for your particular problem.
Public accounts don't measure your chance of relief or harm
People self-test laboratory products for research and describe these experiences publicly; no comparison study has checked their accounts or shown what the drug caused. A placebo injection contains no active medicine for comparison. These accounts come from discussion among users, rather than the studies above. A vivid report won't give you a dependable chance of relief.
Users often describe quickly feeling hot, with their skin turning red. Some say nausea begins within an hour or two and then fades. Others report sickness strong enough to make them stop. Some notice sexual interest arriving unexpectedly, beyond just an erection or other physical response.
Men discuss using the products despite being outside the approved group. People also describe skin darkening after repeated use. Laboratory products can differ in contents and strength, which makes accounts hard to compare. You can't assume each person used the same drug or amount.
PT-141 studies in women found a small gain in desire and frequent nausea. No placebo comparison has checked the personal accounts described here. Your response may differ greatly from the pleasure or disappointment someone describes. Ask your doctor which findings apply to your symptoms and health history.